10 citations
,
September 2014 in “European Journal of Dermatology” This case report describes a 29-year-old woman with longstanding alopecia areata who experienced improvement in her scalp hair loss after 7 years of topical treatment with squaric acid dibutylester.
2 citations
,
March 2015 in “Hepatitis Monthly” This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.
6 citations
,
October 2016 in “Journal of Chemotherapy” This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.
4 citations
,
August 2007 in “PubMed” This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.
26 citations
,
June 2005 in “Journal of The American Academy of Dermatology” In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.